The novel phosphoinositide 3‐kinase–mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of <i>epidermal growth factor receptor</i> mutant lung cancer cells triggered by hepatocyte growth factor
Takako Sano(Kanazawa University), Seiji Yano(Kanazawa University)
Cited by 29
Related Papers
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
|Nature Communications|2020|112
Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in <i>EGFR</i> -T790M Mutant Lung Cancer
|Clinical Cancer Research|2009|97